Zaina P Qureshi

7PUBLICATIONS
20CO-AUTHORS
Cardiology (incl. cardiovascular diseases)Gene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)HaematologyAutoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 29, 2026
Healthcare resource utilization and costs in patients with multiple myeloma administered ciltacabtagene autoleucel in outpatient versus inpatient settings after one to three prior lines of therapy.

|Nov 03, 2025
Healthcare resource utilization and costs in patients with multiple myeloma who received 1 to 3 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, and were exposed to and discontinued lenalidomide in the United States.

Sundar Jagannath, Akshay Kharat, Eric Chinaeke

|Oct 14, 2025
Healthcare cost comparison between first-line ibrutinib and acalabrutinib in chronic lymphocytic leukemia patients in the Veterans Affairs.

Lindsey Fitzgerald, Sabyasachi Ghosh, Alex Bokun

|Apr 22, 2025
A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases.

Kerry A Rogers, Benyam Muluneh, Zaina P Qureshi

|Mar 03, 2022
Correction to: Health-Care and Societal Costs Associated with Non-Persistence with Subcutaneous TNF-α Inhibitors in the Treatment of Inflammatory Arthritis (IA): A Retrospective Observational Study.

Johan Dalén, Anushri Chitkara, Axel Svedbom

|Nov 09, 2021
Health-Care and Societal Costs Associated with Non-Persistence with Subcutaneous TNF-α Inhibitors in the Treatment of Inflammatory Arthritis (IA): A Retrospective Observational Study.

Johan Dalén, Anushri Chitkara, Axel Svedbom

Pageof 2

Frequent Collaborators

2 joint publications

Bruno Emond

2 joint publications

Matthew Perciavalle

1 joint publications

Kerry A Rogers

1 joint publications

Benyam Muluneh